Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/01/2001US20010036481 Modulation of release from dry powder formulations
11/01/2001US20010036479 Having preferred particle size distribution characteristics; antidiabetic agent
11/01/2001US20010036478 Core formulation
11/01/2001US20010036477 Oral administering
11/01/2001US20010036476 Bioavailability; sustained release
11/01/2001US20010036475 Pharmaceutical tablets
11/01/2001US20010036474 Antiemitic agent
11/01/2001US20010036470 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(ii) complexes
11/01/2001US20010036469 Opiate antagonist implant and process for preparation therefor
11/01/2001US20010036462 Enhancing immunology response
11/01/2001US20010036454 Transfection of lung tissue
11/01/2001US20010036451 Embolic compositions
11/01/2001US20010036445 Method of making chewing gum containing colloidal bismuth subcitrate
11/01/2001US20010036444 Anticancer agents
11/01/2001US20010036442 Stool marker
11/01/2001CA2683045A1 Diazabicyclic central nervous system active agents
11/01/2001CA2407672A1 Hydroxyphenstatin and the prodrugs thereof
11/01/2001CA2407663A1 Inhibitors of dipeptidyl peptidase iv
11/01/2001CA2407662A1 Inhibitors of dipeptidyl peptidase iv
11/01/2001CA2407519A1 Daily treatment for erectile dysfunction using a pde5 inhibitor
11/01/2001CA2407507A1 Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
11/01/2001CA2407504A1 Medicine containing polysaccharide substances for activating apoptosis
11/01/2001CA2407493A1 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
11/01/2001CA2407489A1 Triaryl cation antibiotics from environmental dna
11/01/2001CA2407448A1 The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
11/01/2001CA2407445A1 Use of 5-thio-, sulfinyl- and sulfonylpyrazolo¬3,4-b|-pyridines as cyclin dependent kinase inhibitors
11/01/2001CA2407442A1 Novel medicines based on sesquiterpene mixtures
11/01/2001CA2407370A1 Heterocycles that are inhibitors of impdh enzyme
11/01/2001CA2407167A1 Thrombopoietin receptor modulating peptide
11/01/2001CA2407093A1 Substituted phenyl farnesyltransferase inhibitors
11/01/2001CA2407021A1 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
11/01/2001CA2407013A1 Pharmaceutical composition promoting defecation
11/01/2001CA2406998A1 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
11/01/2001CA2406982A1 Zolpidem hemitartrate
11/01/2001CA2406855A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001CA2406652A1 Aminopiperidines for use as glyt-1 inhibitors
11/01/2001CA2406639A1 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001CA2406532A1 Macrocyclic ns-3 serine protease inhibitors of hepatitis c virus compri sing alkyl and aryl alanine p2 moieties
11/01/2001CA2406272A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists
11/01/2001CA2406073A1 A protein kinase c variant to alter memory
11/01/2001CA2406067A1 Compositions comprising the combination of a bile acid and a fibrate for use in therapies for hyperlipidaemia-associated disorders
11/01/2001CA2405992A1 A combination of pinitol and creatine to enhance uptake and retention of creatine
11/01/2001CA2405632A1 Intrathecal administration of rituximab for treatment of central nervous system lymphomas
11/01/2001CA2405565A1 Compounds for treating fibromyalgia and chronic fatigue syndrome
11/01/2001CA2405559A1 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
11/01/2001CA2405543A1 Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
11/01/2001CA2405170A1 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
11/01/2001CA2405138A1 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors
11/01/2001CA2405025A1 (2-aminoethyl) oxime derivatives for the treatment of depression
11/01/2001CA2404998A1 Cytotoxic agents
11/01/2001CA2404970A1 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
11/01/2001CA2404898A1 Ultrashort acting hypnotic barbiturates
11/01/2001CA2402808A1 Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines
11/01/2001CA2402123A1 Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
11/01/2001CA2399741A1 4-hydroxycinnoline-3-carboxyamides as antiviral agents
11/01/2001CA2372673A1 Cyclic amidine compounds
11/01/2001CA2365320A1 Novel heterocyclic compounds
11/01/2001CA2307393A1 Ginsenoside chemotherapy
10/2001
10/31/2001EP1149910A1 Pharmaceutical composition for treating papillomavirus tumours and infection
10/31/2001EP1149906A1 Thrombopoietin receptor modulating peptide
10/31/2001EP1149903A1 ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
10/31/2001EP1149834A1 Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial
10/31/2001EP1149584A1 Use of Photofrin as radiosensitizer
10/31/2001EP1149583A2 Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
10/31/2001EP1149582A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor). Uses thereof
10/31/2001EP1149581A2 Use of rapamycin derivatives in vasculopathies and xenotransplantation
10/31/2001EP1149580A1 Use of heteroaryl substituted N-(Indole-2-Carbonyl-) amides for the manufacture of a medicament for the treatment of infection
10/31/2001EP1149579A2 Use of an estrogen agonist/antagonist for treating female sexual dysfunction
10/31/2001EP1149578A1 Cosmetic or pharmaceutical compositions containing an Argania Spinosa extract
10/31/2001EP1149166A2 GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
10/31/2001EP1149165A1 Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof
10/31/2001EP1149161A2 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
10/31/2001EP1149116A1 Process for the production of multiple cross-linked hyaluronic acid derivatives
10/31/2001EP1149111A1 Method and composition for angiogenesis inhibition
10/31/2001EP1149106A2 4,5-azolo-oxindoles
10/31/2001EP1149105A1 4,5-pyrazinoxindoles as protein kinase inhibitors
10/31/2001EP1149104A2 Pyrrolobenzodiazepine carboxyamide vasopressin agonists
10/31/2001EP1149103A1 Thienylbenzoylbenzazepines as vasopressin agonists
10/31/2001EP1149102A1 Triazolo-pyridazine derivatives as ligands for gaba receptors
10/31/2001EP1149101A1 4-OXO-3,5-DIHYDRO-4$i(H)-PYRIDAZINO 4,5-$i(b)]INDOLE-1-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE
10/31/2001EP1149099A2 Imidazo[4,5-c]-pyridine-4-on-derivatives
10/31/2001EP1149097A2 Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
10/31/2001EP1149096A2 Tricyclic pyridine n-oxides vasopressin agonists
10/31/2001EP1149094A2 4-(aminoalkoxy)benzofurans as n-myristoyltransferase inhibitors
10/31/2001EP1149093A1 4-aryloxindoles as inhibitors of jnk protein kinases
10/31/2001EP1149092A2 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
10/31/2001EP1149091A1 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
10/31/2001EP1149090A1 Potassium salt of ($i(s))-omeprazole
10/31/2001EP1149089A2 Process to prepare cyclic-sulfur fluorine containing oxazolidinones
10/31/2001EP1149087A1 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
10/31/2001EP1149085A1 Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
10/31/2001EP1149083A1 Morpholinobenzamide salts
10/31/2001EP1149082A2 Process for preparing pesticidal intermediates
10/31/2001EP1149080A2 Crystalline form of benzoquinoline-3-one derivative as inhibitor of 5-alpha reductase
10/31/2001EP1149079A1 Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same
10/31/2001EP1149076A1 O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically acceptable salts and process for preparing the same
10/31/2001EP1149074A1 Acetylenic sulfonamide thiol tace inhibitors
10/31/2001EP1149072A1 Sulfonamide hydroxamates
10/31/2001EP1149069A1 Phenylglycine derivatives
10/31/2001EP1149067A1 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents
1 ... 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 5989 5990 5991 5992 5993 5994 5995 5996 5997 5998 ... 7860